By analyzing IDH-1 status, Kim et al. demonstrated increased fluorescence intensity in WHO III gliomas with IDH-1 mutations [4]; in contrast, Ohba et al. found no difference in fluorescence positivity in WHO grade IV gliomas according to IDH-1 status, but no quantification of the fluorescence was performed [27]. The gene discussed is IDH1; the disease is central nervous system cancer.